ReviewNature reviews. Rheumatology2017
Visual loss and other cranial ischaemic complications in giant cell arteritis.
Review in Nature reviews. Rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 170 citations in OpenAlex.
- Giant cell arteritis-related cerebrovascular ischemic events: a French retrospective study of 271 patients, systematic review of the literature and meta-analysis.Arthritis research & therapy · 2023Pooled it
- Endovascular Therapy for Intracranial Giant Cell Arteritis : Systematic Review, Technical Considerations and the Effect of Intra-arterial Calcium Channel Blockers.Clinical neuroradiology · 2022Pooled it
- Article
- Article
- Large vessel vasculitis reframed: integrating conceptual shifts and evidence into practice for Takayasu arteritis and giant cell arteritis.Journal of rheumatic diseases · 2026Review
- Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.Nature reviews. Rheumatology · 2026Review
- What is the optimum incision for superficial temporal artery biopsy? An anatomical study using body donors.Surgical and radiologic anatomy : SRA · 2026Article
- Cranial and Systemic Manifestations of Giant Cell Arteritis: Two Sides of the Same Coin.Cureus · 2026Article
- Quantification of Vascular Burden on Cranial Vessel Wall Magnetic Resonance Imaging and Ophthalmic Complications in Giant Cell Arteritis.ACR open rheumatology · 2026Article
- Orbital MRI for diagnosing giant cell arteritis in cases of anterior ischaemic optic neuropathy.RMD open · 2026Article
- Correlation of vascular enhancement on MRI and clinical manifestations in patients with GCA.Rheumatology advances in practice · 2026Article
- Cardiovascular Risk Factors and Antiphospholipid Antibodies in Giant Cell Arteritis-Related Thrombosis.Archives of rheumatology · 2025Article
- Article
- Vessel wall MRI in giant cell arteritis: standardized protocol and scoring approach developed by an international working group.Rheumatology (Oxford, England) · 2025Review
- Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey.Human vaccines & immunotherapeutics · 2024Article
- Retinal Artery Occlusion: A Review of Current Management Practices.Journal of ophthalmic & vision research · 2024Review
- Sixth cranial nerve palsy in giant cell arteritis: A systematic review.Archives of rheumatology · 2024Article
- Vascular disease persistence in giant cell arteritis: are stromal cells neglected?Annals of the rheumatic diseases · 2024Review
- Multimodality imaging to assess diagnosis and evaluate complications of large vesselarteritis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2024Review
- Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden.RMD open · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) is the most common form of vasculitis in individuals aged 50 years and over. GCA typically affects large and medium-sized arteries, with a predilection for the extracranial branches of the carotid artery. Patients with GCA usually present with symptoms and signs that are directly related to the artery that is affected, with or without constitutional manifestations. The most dreaded complication of GCA is visual loss, which affects about one in six patients and is typically caused by arteritis of the ophthalmic branches of the internal carotid artery. Before the advent of glucocorticoid treatment, the prevalence of visual complications was high. Increasing awareness by physicians of the symptoms of GCA and advances in diagnostic techniques over the past twenty years have also contributed to a substantial decline in the frequency of permanent visual loss. Ischaemic brain lesions are less common than visual lesions, and mostly result from vasculitis of the extradural vertebral or carotid arteries. In the case of both the eye and the brain, ischaemic damage is thought to result from arterial stenosis or occlusion that occurs secondary to the inflammatory process. The inflammatory response at the onset of arteritis, its role as a predictor of complications and the role of traditional cardiovascular risk factors have been extensively investigated in the past decade. In this Review, the epidemiology, risk factors, clinical presentation and current therapeutic approach of GCA-related ischaemic events are discussed, with a particular emphasis on visual loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.